With regard to crizotinib, which has been originally developed as a c-Met inhibitor, the response rate (RR) and progression-free survival (PFS) of crizotinib in first- and second-line settings for advanced ALK+ NSCLC are 74 and 65 % and 10.9 and 7.7 months, respectively, which are significantly better than those achieved with standard chemotherapy [5, 6]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.